Voyager Says Joint Steering Committee With Collaborator Neurocrine Selected A Development Candidate In Gene Therapy Program; Selection Of Candidate Triggered $3M Milestone Payment
Voyager Says Joint Steering Committee With Collaborator Neurocrine Selected A Development Candidate In Gene Therapy Program; Selection Of Candidate Triggered $3M Milestone Payment
Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the fourth quarter of 2024.
選定的開發候選引發了對Voyager的300萬美元里程碑支付，該公司預計將在2024年第四季度收到。
Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program.
根據該項目的進一步推進，Voyager有資格獲得額外的未來開發和商業化里程碑付款。
Under the terms of the 2023 collaboration agreement, for each of the three undisclosed programs, Voyager is eligible to receive up to $175 million in potential development milestone payments plus substantial potential commercial milestone payments, as well as tiered high single-digit to mid-teens royalties on U.S. net sales and mid-single-digit to low double-digit royalties on ex-U.S. net sales. Neurocrine Biosciences will fund the development of each program.
根據2023年合作協議的條款，對於三個未披露的項目中的每一個，Voyager有資格獲得高達1.75億美元的潛在開發里程碑支付，以及大額的潛在商業里程碑支付，以及按照美國淨銷售額和海外淨銷售額分別計提高單位數到中10%的特許高額單數字和中一位數字到低兩位數字的版稅。神經分泌生物科學將爲每個項目提供資金。
譯文內容由第三人軟體翻譯。
